Royce & Associates LP Buys Shares of 18,597 Omnicell, Inc. (NASDAQ:OMCL)

Royce & Associates LP purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 18,597 shares of the company's stock, valued at approximately $811,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Arizona State Retirement System boosted its holdings in shares of Omnicell by 2.9% during the second quarter. Arizona State Retirement System now owns 12,853 shares of the company's stock valued at $348,000 after acquiring an additional 357 shares during the period. Diversified Trust Co raised its stake in Omnicell by 3.3% during the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company's stock valued at $416,000 after purchasing an additional 494 shares during the period. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock worth $55,000 after acquiring an additional 553 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Omnicell by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company's stock valued at $625,000 after acquiring an additional 600 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in Omnicell by 7.4% during the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company's stock worth $265,000 after purchasing an additional 626 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on OMCL. StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Bank of America restated a "neutral" rating and set a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays upped their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Wells Fargo & Company boosted their target price on shares of Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a research report on Monday, October 14th. Finally, Benchmark reissued a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $50.83.

Omnicell Trading Down 1.4 %

Shares of NASDAQ OMCL opened at $41.82 on Thursday. The firm has a fifty day simple moving average of $44.19 and a two-hundred day simple moving average of $37.20. The firm has a market capitalization of $1.94 billion, a PE ratio of -107.23, a price-to-earnings-growth ratio of 35.67 and a beta of 0.81. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.